The company is delivering exceptional 56% year-over-year revenue growth with outstanding cash conversion, but single-product and single-supplier concentration creates a binary risk that the current price leaves little margin for error—and the unfavorable reward/risk geometry with only 5.5% headroom to the take-profit level limits the case for adding exposure.
Thesis pillars
- Inconsistent Earnings Delivery↓Deteriorating
- Industry Leading Revenue Growth↑Improving
- Exceptional Cash Conversion Quality↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 24, 2026· older than 90 days
Kiniksa Pharmaceuticals Interna (KNSA) Stock Analysis
Breakout setup
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $96.12, but acceptable to hold if already in. Reasons: Concentration risk — Product: ARCALYST; Concentration risk — Supplier: Regeneron.
Kiniksa Pharmaceuticals commercializes ARCALYST (rilonacept), an FDA-approved IL-1α/β inhibitor for recurrent pericarditis, as its sole commercial product in the United States, from which it derives substantially all revenue; profits on sales are evenly split with licensor... Read more
Hold if already holding. Not a fresh buy at $96.12, but acceptable to hold if already in. Reasons: Concentration risk — Product: ARCALYST; Concentration risk — Supplier: Regeneron. Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Downgraded from BUY WAIT — price $96.12 vs the analyst target $95.20: -1.0% upside; No upside left. Score 6.5/10, moderate confidence.
Passes 5/8 gates (positive momentum, news events none recent, earnings proximity 109d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity. Suitability: moderate.
About Kiniksa Pharmaceuticals Interna
About Kiniksa Pharmaceuticals Interna
ARCALYST, the first and only FDA-approved therapy for recurrent pericarditis, generates substantially all of Kiniksa Pharmaceuticals' revenue, with the United States as the sole authorized market for commercial sale. FDA approved ARCALYST for recurrent pericarditis in March 2021 for adults and children 12 years and older; Kiniksa estimates the U.S. prevalent patient population at approximately 40,000. In October 2025, pipeline candidate KPL-387 received Orphan Drug Designation from the FDA for the treatment of pericarditis.
Kiniksa sells ARCALYST through a select network of specialty pharmacies, with profits on U.S. sales and third-party proceeds evenly split with Regeneron under the 2017 license agreement. Regeneron currently manufactures and supplies all requirements for both development and commercial use under a Supply Agreement, though a technology transfer to Samsung as replacement drug substance manufacturer is underway. The company's commercial focus targets approximately 14,000 patients with persistent disease and multiple recurrences as a core population, while also expanding reach to a broader first-recurrence cohort of roughly 26,000 additional patients. In 2022, Kiniksa granted Huadong exclusive rights to develop and commercialize ARCALYST in the Asia Pacific region excluding Japan. Clinical-stage asset KPL-387, an IL-1R1 inhibitor designed for monthly subcutaneous dosing, entered Phase 2/3 trials in recurrent pericarditis in July 2025, with Phase 2 data expected in the second half of 2026.
Show full overview
Regeneron serves as the sole manufacturer of ARCALYST drug substance and commercial supply until completion of the Samsung technology transfer. A disruption at Regeneron or a delay in the Samsung qualification process could interrupt commercial supply of Kiniksa's only revenue-generating product. The 10-K specifically identifies delays in the technology transfer as a factor that could materially affect commercialization. Pre-revenue pipeline asset KPL-1161 is targeted for a Phase 1 first-in-human trial by end of 2026, but the company has no alternative commercial revenue source if ARCALYST supply were disrupted.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Kiniksa Pharmaceuticals Interna's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated Oct 28, 2026Recent Developments — Kiniksa Pharmaceuticals Interna
Latest news
- NEWS Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price Target Raised at The Goldman Sachs Group - MarketBeat — MarketBeat Oct 28, 2026 positive
- NEWS Kiniksa (KNSA) Stock Jumps As Q3 Results Fuel Growth Debate - Yahoo Finance — Yahoo Finance Oct 28, 2026 positive
- NEWS Kiniksa (KNSA) Stock Surges As Q3 Earnings Strengthen Its Growth Story - Simply Wall St — Simply Wall St Oct 27, 2026 positive
- NEWS KNSA Stock Climbs As Traders Eye Leadership Shift And Q3 Call - Timothy Sykes — Timothy Sykes Oct 27, 2026 positive
- NEWS Kiniksa Pharmaceuticals Jumps 22% After Raising Sales Outlook - StocksToTrade — StocksToTrade Oct 27, 2026 positive
Latest item Oct 28, 2026 · Generated 2026-11-05T11:34:08Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductARCALYST10-K Item 1A: 'ARCALYST, our sole product, for the treatment of recurrent pericarditis in the United States, where we derive substantially all of our revenue'
- HIGHSupplierRegeneron10-K Item 1: 'Regeneron currently manufactures and supplies all of our requirements of ARCALYST for development and commercial activities'
- HIGHGeographicUnited States10-K Item 1A: 'the United States, where we derive substantially all of our revenue'
Material Events(8-K, last 90d)
- 2026-05-01Item 5.02LOWChief Strategy Officer Eben Tessari resigned effective May 15, 2026, to pursue another executive position in life sciences. Will become consultant and advisor to Science and Research Committee. No disagreement with company operations, policies, or practices cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $96.12, but acceptable to hold if already in. Reasons: Concentration risk — Product: ARCALYST; Concentration risk — Supplier: Regeneron. Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Downgraded from BUY WAIT — price $96.12 vs the analyst target $95.20: -1.0% upside; No upside left. Analyst target $95.20 reached (−1.0%), stop $84.92 (−13.2%), A.R:R -0.1:1. Score 6.5/10, moderate confidence.
Analyst target $95.20 reached (−1.0% from $96.12); no take-profit level is published. Analyst target $95.20 reached (−1.0%), stop $84.92 (−13.2%), A.R:R -0.1:1. Stop-loss: $84.92.
Concentration risk — Product: ARCALYST; Concentration risk — Supplier: Regeneron; Analyst target reached - limited upside remaining.
Kiniksa Pharmaceuticals Interna trades at a P/E of 72.8 (forward 44.0). TrendMatrix value score: 4.6/10. Verdict: Hold.
13 analysts rate KNSA, with a consensus score of 4.3/5. 7 analysts publish price targets averaging $109.
What does Kiniksa Pharmaceuticals Interna do?Kiniksa Pharmaceuticals commercializes ARCALYST (rilonacept), an FDA-approved IL-1α/β inhibitor for recurrent...
Kiniksa Pharmaceuticals commercializes ARCALYST (rilonacept), an FDA-approved IL-1α/β inhibitor for recurrent pericarditis, as its sole commercial product in the United States, from which it derives substantially all revenue; profits on sales are evenly split with licensor Regeneron. The company also has KPL-387 in Phase 2/3 development for the same indication, with Phase 2 data expected in the second half of 2026.